曲奥舒凡对比白消安联合氟达拉滨预处理方案在老年急性髓系白血病或骨髓增生异常综合征患者异基因造血干细胞移植中的随机非劣效3期试验
MC-FludT.14/L是一项开放标签、随机、非劣效3期试验,纳入476例18-70岁、因年龄≥50岁或HSCT特异性合并症指数>2而不适合标准清髓预处理的急性髓系白血病或骨髓增生异常综合征患者,比较曲奥舒凡+氟达拉滨与减强度白消安+氟达拉滨的疗效与安全性。曲奥舒凡方案非劣效于白消安方案,且结局改善提示其可能成为该人群的标准预处理方案。
要点
- 在老年或不适合标准清髓的AML/MDS患者中,曲奥舒凡+氟达拉滨预处理非劣效于减强度白消安+氟达拉滨。
- 两组≥3级不良事件及严重不良事件发生率相近,死亡原因多与移植相关。
核心结论
- 曲奥舒凡联合氟达拉滨预处理在老年或合并症较多的AML/MDS患者异基因HSCT中非劣效于减强度白消安联合氟达拉滨。
- 曲奥舒凡组结局改善提示该方案可能成为该人群的标准预处理方案。
研究设计与样本
- 开放标签、随机、非劣效3期试验,在法国、德国、匈牙利、意大利和波兰的31个移植中心进行。
- 纳入476例18-70岁AML(骨髓原始细胞<5%)或MDS(骨髓原始细胞<20%)、Karnofsky指数≥60%、因年龄≥50岁或HSCT特异性合并症指数>2而不适合标准清髓预处理的异基因HSCT候选患者。
主要发现
- 最常见的≥3级不良事件为血液生化异常(曲奥舒凡组33/221例[15%] vs 白消安组35/240例[15%])和胃肠道疾病(24例[11%] vs 39例[16%])。
- 严重不良事件曲奥舒凡组18例(8%),白消安组17例(7%);死亡原因多与移植相关。
临床怎么用
- 对于因年龄≥50岁或HSCT特异性合并症指数>2而不适合标准清髓预处理的AML/MDS患者,可考虑曲奥舒凡联合氟达拉滨作为异基因HSCT预处理方案。
- 该方案较减强度白消安联合氟达拉滨显著改善2年无事件生存,且安全性相近。
局限性
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. METHODS: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18-70 years, had acute myeloid leukaemia in first or consecutive complete haematological remission (blast counts <5% in bone marrow) or myelodysplastic syndrome (blast counts <20% in bone marrow), Karnofsky index of 60% or higher, and were indicated for allogeneic HSCT but considered at an increased risk for standard myeloablative preparative regimens based on age (≥50 years), an HSCT-specific comorbidity index of more than 2, or both. Patients were randomly assigned (1:1) to receive either intravenous 10 g/m2 treosulfan daily applied as a 2-h infusion for 3 days (days -4 to -2) or 0·8 mg/kg busulfan applied as a 2-h infusion at 6-h intervals on days -4 and -3. Both groups received 30 mg/m2 intravenous fludarabine daily for 5 days (days -6 to -2). The primary outcome was event-free survival 2 years after HSCT. The non-inferiority margin was a hazard ratio (HR) of 1·3. Efficacy was assessed in all patients who received treatment and completed transplantation, and safety in all patients who received treatment. The study is registered with EudraCT (2008-002356-18) and ClinicalTrials.gov (NCT00822393). FINDINGS: Between June 13, 2013, and May 3, 2016, 476 patients were enrolled (240 in the busulfan group received treatment and transplantation, and in the treosulfan group 221 received treatment and 220 transplanation). At the second preplanned interim analysis (Nov 9, 2016), the primary endpoint was met and trial was stopped. Here we present the final confirmatory analysis (data cutoff May 31, 2017). Median follow-up was 15·4 months (IQR 8·8-23·6) for patients treated with treosulfan and 17·4 months (6·3-23·4) for those treated with busulfan. 2-year event-free survival was 64·0% (95% CI 56·0-70·9) in the treosulfan group and 50·4% (42·8-57·5) in the busulfan group (HR 0·65 [95% CI 0·47-0·90]; p<0·0001 for non-inferiority, p=0·0051 for superiority). The most frequently reported grade 3 or higher adverse events were abnormal blood chemistry results (33 [15%] of 221 patients in the treosulfan group vs 35 [15%] of 240 patients in the busulfan group) and gastrointestinal disorders (24 [11%] patients vs 39 [16%] patients). Serious adverse events were reported for 18 (8%) patients in the treosulfan group and 17 (7%) patients in the busulfan group. Causes of deaths were generally transplantation-related. INTERPRETATION: Treosulfan was non-inferior to busulfan when used in combination with fludarabine as a conditioning regimen for allogeneic HSCT for older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. The improved outcomes in patients treated with the treosulfan-fludarabine regimen suggest its potential to become a standard preparative regimen in this population. FUNDING: medac GmbH.
引用
- Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2019. PMID: 31606445. doi:10.1016/S2352-3026(19)30157-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。